Reem Alsolami
YOU?
Author Swipe
View article: Acute and chronic impact of interleukin-33 stimulation on chemokines and growth factors in human cord blood-derived mast cells
Acute and chronic impact of interleukin-33 stimulation on chemokines and growth factors in human cord blood-derived mast cells Open
Background Mast cells (MCs) are multifaceted immune cells that are capable of recognizing and responding to various stimuli by releasing an array of cytokines. We aimed to use human cord blood-derived mast cells (hCBMCs) as a model to eval…
View article: Computational Design and Optimization of Peptide Inhibitors for SIRT2
Computational Design and Optimization of Peptide Inhibitors for SIRT2 Open
Sirtuin 2 (SIRT2), an NAD+-dependent deacetylase, is crucial for regulating vital physiological processes, including aging, DNA repair, and cell cycle progression. Its abnormal activity is linked to diseases such as Parkinson’s disease, ca…
View article: Acute and prolonged effects of interleukin-33 on cytokines in human cord blood-derived mast cells
Acute and prolonged effects of interleukin-33 on cytokines in human cord blood-derived mast cells Open
Mast cells are multifaceted cells localized in tissues and possess various surface receptors that allow them to respond to inner and external threat signals. Interleukin-33 (IL-33) is a cytokine released by structural cells in response to …
View article: Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. Nanomaterials 2022, 12, 4029
Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. Nanomaterials 2022, 12, 4029 Open
In the original publication [...]
View article: Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies
Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies Open
Utilizing a custom panel allowed us to identify variants that were not detected by routine tests or those that were not routinely investigated. Using the costuming panel will enable us to sequence all genes and discover new potential patho…
View article: Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells
Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells Open
6-Mercaptopurine (6-MP) is a well-known immunosuppressive medication with proven anti-proliferative activities. 6-MP possesses incomplete and highly variable oral absorption due to its poor water solubility, which might reduce its anti-can…
View article: Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features Open
View article: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups
Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups Open
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
View article: Characterisation of the mutational landscape of chronic lymphocytic leukaemia using genome-wide approaches
Characterisation of the mutational landscape of chronic lymphocytic leukaemia using genome-wide approaches Open
Chronic lymphocytic leukaemia (CLL) is characterised by a chronically relapsing course and clinical and biological heterogeneity, and none of the conventional treatment options are curative. CLL cases lack disease-defining mutations but th…
View article: Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia Open
View article: Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL Open
Key Points Targeted NGS of relapsed/refractory CLL reveals a high incidence of concurrent mutations that mostly affect the TP53, ATM, and SF3B1 genes. Concurrent mutations of the TP53, ATM, and/or SF3B1 genes confer short survival in patie…